Prognostic factors of survival of HIV-infected patients with cytomegalovirus disease: Aquitaine cohort, 1986-1997

European Journal of Epidemiology

Volumn 16, Issue 5, 2000, Pages 425-432

  Binquet, C ^a   Saillour, F ^a,b   Bernard, N ^c   Rougier, M B ^d   Leger, F ^d   Bonnal, F ^e   Dabis, F ^a,b  

^a INSERM   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d HÔPITAL PELLEGRIN   (France)

^e CENTRE HOSPITALIER DE LA CÔTE BASQUE   (France)

Author keywords

Cytomegalovirus; HIV; Opportunistic infections; Prognostic factors; Protease inhibitors; Survival

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PROGNOSIS; SURVIVAL RATE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS RETINITIS; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEMOPHILIA A; HETEROSEXUALITY; HIV PROTEASE INHIBITORS; HOMOSEXUALITY; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0033851236     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007627508918     Document Type: Article

References (41)

1. Lessons from the natural history of cytomegalovirus
2. Preventing opportunistic infections in persons infected with HIV: 1997 guidelines
3. Antiretroviral therapy for HIV infection in 1998. Updated recommandations of the international AIDS-society panel
4. 1998 Revision to the British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals
5. Consequences for the management of cytomegalovirus
6. Advances in the management of AIDS-related Cytomegalovirus retinitis
7. Regression of Cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS
8. Randomised placebo-controlled trial of Ritonavir in advanced HIV-1 disease
9. Management of Cytomegalovirus disease
10. Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system, 1985-1995
11. Elargissement des criteres de la categorie 'contamination heterosexuelle' dans le cadre de la surveillance du SIDA en France
12. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
13. Regression models and life tables (with discussion)
14. High-level sensitivity of quantitative pp65 Cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up
15. Polymerase Chain Reaction detection of Cytomegalovirus DNA in peripheral blood leukocytes as a predictor of Cytomegalovirus disease in HIV-infected patients
16. Incidence of Cytomegalovirus disease in the Aquitaine Cohort of HIV-infected patients: A retrospective survey, 1987-1993
17. Predictive factors of occurrence of Cytomegalovirus disease and impact on survival in the Aquitaine Cohort in France, 1985 to 1994
18. Serious Cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS)
19. Mortality of patients with the Acquired Immunodeficiency Syndrome treated with either foscarnet or ganciclovir for Cytomegalovirus retinitis
20. Cytomegalovirus disease in AIDS: The Edinburgh experience
21. Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: Increasing incidence, unchanged prognosis
22. Toxoplasmosis in Danish AIDS patients
23. Temporal trends and factors associated with survival after Pneumocystis carinii pneumonia in California, 1983-1992
24. Incidence and natural history of Cytomegalovirus disease in patients with advanced Human Immunodeficiency Virus disease treated with zidovudine
25. Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival
26. Cytomegalovirus encephalitis in Acquired Immunodeficiency Syndrome (AIDS)
27. Diagnosing and treating Cytomegalovirus pneumonia in patients with AIDS
28. Impact of opportunistic disease on survival in patients with HIV infection
29. Determinants of survival in HIV-positive patients
30. A randomized, controlled trial of foscarnet in the treatment of Cytomegalovirus retinitis in patients with AIDS
31. Cytomegalovirus infection in patients with AIDS
32. Foscarnet decreases Human Immunodeficiency Virus RNA
33. Current management of Cytomegalovirus disease in patients with AIDS
34. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France 1995 to 1997
35. A controlled trial of two nucleoside analogues plus Indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less
36. Increasing survival in AIDS patients with Cytomegalovirus retinis treated with combination antiretroviral therapy including HIV protease inhibitors
37. Decrease of Cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy
38. Restoration of Cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
39. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy